KalVista Pharma Executives Engage in Insider Trading, Selling Millions in Stock

Insider Trading at KalVista Pharma

KalVista Pharma, a biopharmaceutical company focused on developing treatments for hereditary angioedema, has seen several of its executives engage in insider trading. According to reports, the company's Chief Medical Officer (CMO), Audhya, sold $83,000 in shares ^[1]. This move has sparked interest among investors and analysts, who are closely monitoring the company's stock performance.

Insider Trading Activity

In the past 24 hours, several KalVista Pharma executives have been involved in insider trading. The company's CFO, Seifert, sold $7.7 million in stock ^[2], while the Chief Commercial Officer (CCO), Sweeny, sold $61,878 in stock ^[3]. Additionally, the company's Chief Development Officer sold $67,668 in stock ^[4].

Tax Obligations

One of the executives, CEO Palleiko, sold $156,000 in shares to cover tax obligations ^[5]. This move has raised questions about the company's financial health and the motivations behind these insider trades.

Market Reaction

The insider trading activity at KalVista Pharma has had a significant impact on the company's stock price. The stock has seen a notable increase in value, with some analysts attributing this to the company's strong earnings and the potential for future growth.

Sources

[1] KalVista Pharma CMO Audhya sells $83k in shares
[2] Cloudflare (NET) CFO Seifert sells $7.7 million in stock
[3] KalVista Pharma CCO Sweeny Sold $61,878 in Stock
[4] KalVista Pharma chief development officer sells $67,668 in stock
[5] Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations